Introduction
Early gastric cancer is defi ned as a tumor confi ned to the mucosa or submucosa, irrespective of lymph node metastasis. In Japan, the 5-year survival rate of early gastric cancer is reported to exceed 90%. When early gastric cancer is classifi ed into mucosal and submucosal tumors, the prognosis of submucosal cancer is worse than that of mucosal cancer. Lymph node metastases are present in only 3%-5% of patients with mucosal cancer, versus 10%-25% of those with submucosal cancer. Many investigations of early gastric cancer have shown that the existence of lymph node metastasis decreases the survival rate, and that such metastasis is common in patients with submucosal cancer, particularly if the tumor is 4 cm or more in diameter and is of the diffuse type with vascular invasion. In general, metastasis of early gastric cancer to sites other than lymph nodes is very rare. Even in patients with early gastric carcinoma, lymph node metastasis is regarded as having a signifi cant infl uence on the prognosis and the selection of treatment. Several clinicopathological factors, such as the tumor size, tumor stage, lymphatic invasion, and penetrating growth, are known to be correlated with lymph node metastasis [1] [2] [3] .
Recently, several biological markers have attracted attention because of their correlations with tumor invasion and metastasis [1] [2] [3] [4] [5] [6] [7] [8] . Such biological markers may identify tumors with higher invasiveness and more aggressive biological behavior. There have been many reports about a strong correlation between certain biological markers and the presence of regional lymph node metastasis [1] [2] [3] [4] [5] [6] [7] [8] .
S-100 protein-positive dendritic cells (DCs) are recognized as the most effective antigen-presenting cells involved in the induction of the primary immune response, and thus are considered to be the best vehicle for the delivery of tumor-specifi c antigens when performing immunotherapy for cancer [9, 10] . Infi ltration Abstract Background. We aimed to elucidate clinicopathological variables associated with lymph node metastasis of submucosal invasive gastric cancer. Methods. Specimens were surgically resected from 201 patients who had primary submucosal gastric cancer. We studied 39 consecutive patients with lymph node metastasis and 162 patients without lymph node metastasis. We compared the following clinicopathological characteristics of the patients in relation to lymph node metastasis: age, sex, tumor size, histology, extent of submucosal invasion, lymphatic and venous invasion, and ulceration of the tumor. Submucosal invasion was divided subjectively into sm1, sm2, and sm3 (representing invasion of the upper-, middle-, and lower-third of the submucosa, respectively). We also studied the relationship between lymph node metastasis of submucosal gastric cancer and immunohistochemistry for p53, Ki67, vascular endothelial growth factor (VEGF), a-fetoprotein, sLe a , and dendritic cells (DCs). Results. In terms of conventional pathological factors, lymph node metastasis in submucosal gastric cancer was related to tumor size (P = 0.002), depth of submucosal invasion (P = 0.001), lymphatic invasion (P < 0.0001), and venous invasion (P = 0.012). Lymph node metastasis in sm1 gastric cancer was signifi cantly related to VEGF expression (P = 0.047). Also, lymph node metastasis in sm3 gastric cancer was signifi cantly correlated with DC expression (P = 0.016). Multivariate analysis showed that tumor size, tumor invasion depth in the submucosal layer, and lymphatic invasion were independent predictors of nodal metastasis in submucosal gastric cancer. Conclusion. Conventional pathological factors, such as tumor size, depth of submucosal invasion, and lymphatic invasion, have a signifi cant infl uence on lymph node metastasis. VEGF expression and DC expression may be helpful predictors of lymph node metastasis in patients with sm1 and sm3 gastric cancer, respectively.
Key words DC · Lymph node metastasis · Submucosal gastric cancer · VEGF of DCs is believed to be governed by factors such as the specifi c immunity of tumor cells. Prominent infi ltration of DCs is well correlated with survival in patients who have gastric, esophageal, colorectal, or lung cancer [11] [12] [13] [14] [15] . When autologous DCs were administered in a clinical trial as a vaccine for B-cell lymphoma, host immunity was stimulated and an anticancer effect was noted [9, 10] .
The use of endoscopic resection for early gastric cancers has increased in recent years, with advances in the technique. Most patients with histologically differentiated-type mucosal gastric cancer can be completely cured by this technique. However, the treatment criteria for the endoscopic treatment of submucosal gastric cancers remain controversial because of the high risk of lymph node metastasis. Therefore, the possibility of endoscopic resection for submucosal gastric cancers needs to be examined thoroughly as the population ages. In patients with submucosal gastric cancer, gastrectomy with lymph node dissection is generally performed. It is necessary to determine the indications for postoperative adjuvant chemotherapy in patients with submucosal cancer to achieve a better therapeutic outcome. A combination of the above-mentioned biological properties and host defense markers may assist in the prediction of lymph node metastasis before and after treatment. In the present study, we analyzed conventional clinicopathological features in patients with submucosal gastric cancer to assess the relationship of these features with lymph node metastasis. The expression of p53, Ki67, vascular endothelial growth factor (VEGF), α-fetoprotein, sLe a , and DC in submucosal gastric cancer was also studied. Furthermore, we compared immunohistochemical features in patients with and without lymph node metastasis.
Patients and methods
From 1992 to 2000 at the Toyohashi Municipal Hospital, specimens were surgically resected from 201 patients with primary submucosal gastric cancer. The specimens were examined pathologically, including detection of lymph node metastasis. Informed consent was obtained from each patient. All resected specimens were cut into 5-mm serial sections, and sections through the maximum diameter of the lymph node were routinely stained with hematoxylin and eosin for light microscopic examination.
We studied 39 consecutive patients with lymph node metastasis and 162 patients without lymph node metastasis. We compared the following clinicopathological characteristics of the patients in relation to lymph node metastasis: age, sex, tumor size, histology, extent of submucosal invasion, lymphatic and venous invasion, and ulceration of the tumor. The tumors were histologically classifi ed as differentiated and undifferentiated types according to the criteria of the Japanese Research Society for Gastric Cancer. Differentiated type consisted of papillary and tubular adenocarcinomas; and undifferentiated type included poorly differentiated adenocarcinomas, signet ring cell carcinomas, and mucinous adenocarcinomas. Submucosal invasion was divided subjectively into three categories: sm1, sm2, and sm3 (representing invasion of the upper-, middle-, and lower-third of the submucosa, respectively). Also, the vertical depth of tumor invasion into the submucosa was measured from the muscularis mucosae. The extent of lymphatic and venous invasion was divided subjectively into four categories: none (0), slight (1), moderate (2), and severe (3). Patients were divided into the sm1 gastric cancer group, sm2 gastric cancer group, and sm3 gastric cancer group. There were 61 patients with sm1 gastric cancer and 73 patients with sm3 gastric cancer.
Immunohistochemistry
A paraffi n-embedded section from each specimen block was stained with hematoxylin and eosin for histological evaluation, and representative blocks were used for immunohistochemical studies. For this study, we investigated 38 consecutive patients with lymph node metastasis and 153 patients without lymph node metastasis. We compared the following immunohistochemical features in relation to lymph node metastasis: p53 expression [1] , Ki67 expression [2, 3] , VEGF expression [7, 14, 15] , α-fetoprotein expression [4, 5] , sLe a expression [6] , and DC expression [10] [11] [12] [13] [14] [15] . Immunohistochemical staining was performed by the streptavidin-biotinperoxidase complex method with a LSAB2 kit (Dako Cytomation, Denmark) and diaminobenzideine (DAB) to visualize the substrate. The primary antibodies were anti-p53 (clone DO-7; Dako Cytomation), anti-Ki 67 (clone MIB-1; Dako Cytomation), polyclonal anti-VEGF (Santa Cruz Biotechnology, USA), polyclonal anti-α-fetoprotein (Dako Cytomation), anti-Sialyl Lewis a (clone C241 : 5 : 1 : 4; Novocastra Laboratories, UK), and polyclonal anti-S100 (Dako Cytomation). Antigen retreival was performed by microwave treatment in citrate buffer (pH 6.0) before immunostaining. The fi ndings were classifi ed as follows: (0), no stained cells; (1+), scattered positive cells; (2+), nests of positive cells; (3+), diffuse positive cells; and (±), between (−) and (1+). For the nuclear staining of p53 and Ki67, the intensity of tumor-cell staining was evaluated as follows: (0), 0%; (±), 1%-9% of tumor cells; (1+), 10%-40% of tumor cells; (2+), 41%-80% of tumor cells; and (3+), more than 80% of tumor cells (see Fig. 1 for examples of staining results). Slides were examined by one inves-tigator who had no knowledge of the corresponding clinicopathologic data.
Statistical analysis
All marker analyses were blinded to patient outcome. Statistical analysis was performed with the χ 2 test and the Mann-Whitney U-test. The infl uence of each variable on lymph node metastasis was assessed by multivariate logistic regression analysis, using SPSS software. The level of signifi cance was set at P < 0.05.
Results

Relationship between histopathological fi ndings and lymph node metastasis in all patients with submucosal cancer
Among the 201 patients with submucosal gastric cancer, 39 (19.4%) were histologically shown to have lymph node metastasis and 162 (80.6%) had no lymph node metastasis. The average tumor sizes in the patients with and without lymph node metastasis were 42.8 ± 27.8 mm versus 30.2 ± 19.2 mm, respectively (mean ± SD; P = 0.002). The number of patients with sm1, sm2, and sm3 tumors among those with and without lymph node metastasis was 7, 11, and 21 versus 54, 56, and 52, respectively (P = 0.007). The depth of submucosal tumor invasion in the patients with and without lymph node metastasis was 3.14 ± 2.37 mm versus 1.86 ± 1.83 mm, respectively (mean ± SD; P = 0.001). The number of patients with ly0, ly1, ly2, and ly3 among those with and without lymph node metastasis was 6, 14, 15, and 4 versus 108, 33, 15, and 6, respectively (P < 0.0001). The number of patients with v0, v1, v2, and v3 among those with and without lymph node metastasis was 22, 11, 6, and 0 versus 128, 21, 8, and 3, respectively (P = 0.012). There were no signifi cant differences in age, sex ratio, histology, and ulceration of the tumor focus between the patients with and without lymph node metastasis (Table 1) .
Sm1 gastric cancer group (slight submucosal invasion)
Among the 61 patients with sm1 submucosal gastric cancer, 7 (11.5%) were histologically shown to have lymph node metastasis and 54 (88.5%) had no lymph node metastasis. The average depth of submucosal invasion in the patients with and without lymph node metastasis was 0.85 ± 0.64 mm versus 0.43 ± 0.42 mm, respectively (mean ± SD; P = 0.039). The number of patients with ly0, ly1, ly2, and ly3 among those with and without lymph node metastasis was 1, 3, 2, and 1 versus 45, 9, 0 and 0, respectively (P < 0.0001). The number of patients with v0, v1, v2, and v3 among those with and without lymph node metastasis was 5, 2, 0, and 0 versus 49, 2, 1 and 0, respectively (P = 0.049). There were no signifi cant differences in age, sex ratio, tumor size, histology, and ulceration of the tumor focus between the patients with and without lymph node metastasis ( Table 2) .
Sm3 gastric cancer group (massive submucosal invasion)
Among the 73 patients with sm3 submucosal gastric cancer, 21 (28.8%) were histologically shown to have lymph node metastasis and 52 (71.2%) did not have lymph node metastasis. The number of patients who had ly0, ly1, ly2, and ly3 among those with and without lymph node metastasis was 2, 5, 11, and 3 versus 23, 16, 9, and 4, respectively (P = 0.005). The number of patients who had v0, v1, v2, and v3 among those with and without lymph node metastasis was 9, 7, 5, and 0 versus 37, 9, 3, and 3, respectively (P = 0.025). There were no signifi cant differences in age, sex ratio, tumor size, histology, tumor invasion depth in the submucosal layer, and ulceration of the tumor focus between the patients with and without lymph node metastasis (Table 3) .
Relationship between immunohistochemical fi ndings and lymph node metastasis in patients with submucosal cancer
Among the 191 patients with submucosal gastric cancer examined for this part of the study, 38 (19.9%) were histologically shown to have lymph node metastasis and 153 (80.1%) had no lymph node metastasis. The number of patients with p53 expression graded as 0, ±, 1+, 2+, and 3+ among those with and without lymph node metastasis was 13, 0, 5, 10, and 9 versus 38, 17, 45, 26, and 24, respectively (P = 0.420). The number of patients with Ki 67 expression graded as 0, ±, 1+, 2+, and 3+ among those with and without lymph node metastasis was 0, 1, 10, 21, and 6 versus 1, 2, 43, 83, and 23, respectively (P = 0.885). The number of patients with VEGF expression graded as 0, ±, 1+, 2+, and 3+ among those with and without lymph node metastasis Submucosal carcinomas were classifi ed into three categories according to depth of invasion by dividing the submucosal layer into three equal parts, sm1 (superfi cial), sm2 (intermediate), and sm3 (deep) a Mann-Whitney U-test for differences in age, tumor size, and tumor invasion depth in the submucosal layer, otherwise χ 2 text b Differentiated type, papillary and tubular adenocarcinomas; undifferentiated type, poorly differentiated adonocarcinomas; signet ring cell carcinomas, and mucinous adenocarcinomas c Extent of lymphatic and venous invasion, as defi ned in "Patients and methods" section graded as 0, ±, 1+, 2+, and 3+ among those with and without lymph node metastasis was 32, 6, 0, 0, and 0 versus 112, 17, 13, 7, and 2, respectively (P = 0.115; Table  4 ).
Sm1 gastric cancer group (slight submucosal invasion)
Among the 59 patients with sm1 submucosal gastric cancer, 7 (11.9%) were histologically shown to have lymph node metastasis and 52 (88.1%) had no lymph node metastasis. The number of patients with VEGF expression graded as 0, ±, 1+, 2+, and 3+ among those with and without lymph node metastasis was 4, 0, 2, 0, and 0 versus 48, 1, 3, 0, and 0, respectively (P = 0.047). There were no signifi cant differences in immunostaining for p53, Ki57, α-fetoprotein, sLe a , and DC between patients with and without lymph node metastasis (Table 5 ).
Sm3 gastric cancer group (massive submucosal invasion)
Among the 71 patients with sm3 submucosal gastric cancer, 20 (28.2%) were histologically shown to have lymph node metastasis and 51 (71.8%) had no lymph node metastasis. The number of patients with DC expression graded as 0, ±, 1+, 2+, and 3+ among those with and without lymph node metastasis was 17, 3, 0, 0, and 0 versus 29, 7, 8, 5 and 1, respectively (P = 0.016). There were no signifi cant differences in the other immunohistochemical markers, tested, i.e., p53, Ki57, VEGF, α-fetoprotein, and sLe a , between patients with and without lymph node metastasis (Table 6 ).
Multivariate analysis of factors related to lymph node metastasis
Multivariate analysis using the logistic regression model demonstrated that several conventional clinicopathological factors, including tumor size (P = 0.021), tumor invasion depth in the submucosal layer (P = 0.027), and lymphatic vessel invasion (P < 0.0001) were correlated with lymph node metastasis. However, the immunohistochemical markers, including VEGF expression (P = 0.098) and sLe a expression (P = 0.120), were not independent predictors of lymph node metastasis in submucosal gastric cancer (Table 7) .
Discussion
Despite advances in surgery and adjuvant chemotherapy, most deaths in cancer patients are still caused by metastasis. Lymph node metastasis is known to be one of the major negative prognostic factors for gastric carcinoma. Patients with early gastric cancer and lymph node metastasis have a relatively poor survival rate compared to patients without lymph node metastasis. Thus, when treatment of early gastric cancer is considered, the absence of lymph node metastasis is the most important factor in predicting curability. Because lymph node metastases are present in 10%-25% of patients with submucosal tumors, it is important to assess the presence of lymph node metastasis when we are operating on submucosal gastric cancer and to devise a treatment strategy for nodal metastasis. Many studies have already attempted to defi ne the risk factors for lymph node metastasis of submucosal gastric cancer; these factors include a larger tumor size, deep invasion of the submucosa, tumor ulceration, and lymphatic involvement [1] [2] [3] . In our study, lymph node metastasis of submucosal gastric cancer was clinicopathologically related to tumor size, the depth of submucosal invasion, lymphatic invasion, and venous invasion. However, among the patients with same clinicopathological fi ndings, there were some patients with lymph node metastasis and some without lymph node metastasis. What accounts for this difference? There are some patients in whom conventional clinicopathological fi ndings fail to provide a good marker of the absence or presence of lymph node metastasis. To curatively treat submucosal invasive gastric cancer with a high incidence of lymph node metastasis, precise new biological markers that can predict the presence of lymph node metastasis are needed. In the present study, we searched for such new markers by examining the relationship between clinicopathological or immunohistochemical fi ndings and lymph node metastasis.
Recent developments in molecular biology have begun to demonstrate that the metastatic process is related to the interaction between tumor cells and their micro-environment, including angiogenic factors (tumor vascularization), proteolytic enzymes, adhesion molecules, growth factors, and oncogenes. Patients with strong immune defenses against cancer, as indicated by marked infi ltration of dendritic cells (DCs), appear to have a better prognosis [10] [11] [12] [13] [14] . p53 is a tumor suppres-sor gene that plays an important role in the cell cycle and mediates the induction of apoptosis or recovery from DNA damage. When mutant p53 protein is expressed, these functions are often blocked. It has been reported that p53 acts as a tumor growth regulator, and a correlation between p53 positivity and the presence of regional lymph node metastasis has been noted [1] . Ki-67 is a nuclear antigen that is detected in proliferating but not resting cells. A high Ki-67 labeling index (LI) at the deepest site of tumor penetration indicates an environment that promotes invasion and metastasis [2, 3] . Carbohydrate antigen (CA) 19-9 is a cancerassociated antigen detected by the monoclonal antibody NS 19-9 that has been shown to recognize sialyl Lewis A (sialyl Lea). Recently, sialyl Lea has been reported to act as a ligand for the selectin family, which mediates cell-to-cell adhesion. The expression of sialyl Lea has also been reported as a prognostic factor for gastric carcinoma [6] . Many authors have reported on the relationship between the malignant potential of tumors and angiogenesis. Vascular endothelial growth factor (VEGF) is an angiogenic factor, and is known to play a crucial role in neovascularization [7, 14, 15] . It is well known that the prognosis of α-fetoprotein-positive cancer is extremely poor once lymph node metastasis has occurred, even if the tumor is limited to the submucosa. α-fetoprotein-producing early gastric cancers are recognized to have a high incidence of lymph node metastasis, lymphatic invasion, venous invasion, and liver metastasis [4, 5] . S-100 protein-positive DCs are the most effective antigen-presenting cells for induction of the primary immune response and are considered to be the best vehicle for the delivery of tumor-specifi c antigens for immunotherapy [9] . Dendritic cells (DCs) can induce T-cell growth and they also participate in antitumor immunity. Thus, tumor infi ltration of DCs has been associated with a better prognosis of advanced gastric cancer [11] [12] [13] [14] [15] . The above biomarkers have been reported to be associated with both lymph node metastasis and the prognosis of gastric carcinoma. However, few authors have studied multiple tumor markers and host-defense markers simultaneously in patients with submucosal gastric cancer. Accordingly, we studied the relationship between lymph node metastasis in submucosal gastric cancer and immunohistochemistry for p53, Ki67, VEGF, α-fetoprotein, sLe a , and DC. In the whole submucosal gastric cancer group, there were no significant differences in immunohistochemical parameters between those with and without lymph node metastasis. However, the Mann-Whitney U-test showed that lymph node metastasis in sm1 gastric cancer was related to VEGF expression. Also, lymph node metastasis in sm3 gastric cancer was signifi cantly correlated with DC expression by the Mann-Whitney U-test. Multivariate analysis of factors related to lymph node metastasis showed that immunohistochemical fi ndings for biological markers, such as VEGF expression and sLe a expression, were helpful; however, they were not independent predictors of nodal metastasis in submucosal gastric cancer.
It is reasonable to expect that useful information could be obtained by comparing the clinicopathological features and immunohistochemical expression of biological markers in patients with and without lymph node metastasis. Recent studies have shown that targeted agents improved survival in patients with advancedstage colorectal cancer. Bevacizumab, a monoclonal antibody targeting VEGF, is the fi rst antiangiogenic drug to show improved effi cacy when used in combination with irinotecan and oxaliplatin, compared with irinotecan and oxaliplatin alone, for fi rst-and second-line treatment of colorectal cancer [16] . Several immunotherapeutic strategies are being employed at present to combat B-cell malignancies. Active immunotherapies include vaccination strategies with DCs and genetically modifi ed tumor cell preparations, as well as DNA and protein vaccination [9] . Combined analysis of conventional pathological factors (such as tumor size, depth of submucosal invasion, and lymphatic invasion), immunohistochemical factors (such as VEGF), and host defense factors (such as DC expression) may be helpful for the detection of lymph node metastasis and for developing new treatment strategies for submucosal gastric cancer.
In conclusion, conventional pathological factors, such as tumor size, depth of submucosal invasion, and lymphatic invasion, have a signifi cant infl uence on lymph node metastasis. In addition, VEGF expression and DC expression may be helpful predictors of lymph node metastasis in patients with sm1 gastric cancer and sm3 gastric cancer, respectively.
